With a point-of-care electrodiagnostic device for the diagnosis of neuropathies, NeuroMetrix has set out to change how primary care physicians provide patient care. That means it faces the challenge of achieving market coverage on the scale of a pharmaceutical sales force, while at the same time providing the kinds of training and support that go hand-in-hand with a device business. This is a tall order for a small company. Fortunately, NeuroMetrix's timing is great. Over the years, it has expanded its testing platform from the diagnosis of carpal tunnel syndrome and low back pain to the detection of diabetic neuropathy. It thus finds itself the sole purveyor of a technology that can, at the point of care, detect diabetic neuropathy even before symptoms develop, and it has come to market just at the time when Eli Lilly and others getting close to market with drugs that treat not only the symptoms of diabetic neuropathy, but influence its course. .
By Mary Stuart
Shai Gozani, MD, PhD, president and CEO of NeuroMetrix Inc. says that his company aims to build a business...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
